Literature DB >> 7199515

Serum concentrations of total and non-protein-bound oestradiol in patients with breast cancer and in normal controls.

J W Moore, G M Clark, R D Bulbrook, J L Hayward, J T Murai, G L Hammond, P K Siiteri.   

Abstract

In premenopausal women with breast cancer, total serum oestradiol (E2) concentrations are normal but nonprotein-bound E2 concentration are significantly raised. This is not due to low sex-hormone-binding-globulin (SHBG) binding capacities which are within the normal range and is unlikely to be due to the small but significant decrease in albumin concentrations. In post-menopausal patients, both total and non-protein-bound E2 are significantly raised: this may be explained partially by lower SHBG binding capacities. In patients and controls there is a highly significant correlation between non-protein-bound E2 and SHBG but, for a given SHBG binding capacity, the patients have more non-bound E2 than controls. It is concluded that the breast in women with breast cancer may be exposed to elevated levels of biologically active E2 although the reasons for this remain obscure.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7199515     DOI: 10.1002/ijc.2910290105

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Serum hormone levels in pre-menopausal Chinese women in Shanghai and white women in Los Angeles: results from two breast cancer case-control studies.

Authors:  L Bernstein; J M Yuan; R K Ross; M C Pike; R Hanisch; R Lobo; F Stanczyk; Y T Gao; B E Henderson
Journal:  Cancer Causes Control       Date:  1990-07       Impact factor: 2.506

Review 2.  Epidemiology and endocrinology of benign breast disease.

Authors:  D Y Wang; I S Fentiman
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

Review 3.  Sex hormone-binding globulin: not only a transport protein. What news is around the corner?

Authors:  N Fortunati
Journal:  J Endocrinol Invest       Date:  1999-03       Impact factor: 4.256

Review 4.  Factors influencing estrogen production and metabolism in postmenopausal women with endocrine cancer.

Authors:  V H James; E J Folkerd; R C Bonney; P A Beranek; M J Reed
Journal:  J Endocrinol Invest       Date:  1982 Sep-Oct       Impact factor: 4.256

5.  The relation of reported alcohol ingestion to plasma levels of estrogens and androgens in premenopausal women (Maryland, United States).

Authors:  J F Dorgan; M E Reichman; J T Judd; C Brown; C Longcope; A Schatzkin; W S Campbell; C Franz; L Kahle; P R Taylor
Journal:  Cancer Causes Control       Date:  1994-01       Impact factor: 2.506

6.  Chemoprevention of breast cancer.

Authors:  T J Powles; J R Hardy; S E Ashley; D Cosgrove; J B Davey; M Dowsett; A McKinna; A G Nash; S K Rundle; H D Sinnett
Journal:  Breast Cancer Res Treat       Date:  1989-10       Impact factor: 4.872

7.  A pilot study of urinary estrogen metabolites (16alpha-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer.

Authors:  G Ursin; S London; F Z Stanczyk; E Gentzschein; A Paganini-Hill; R K Ross; M C Pike
Journal:  Environ Health Perspect       Date:  1997-04       Impact factor: 9.031

Review 8.  Endogenous estrogens and breast cancer risk: the case for prospective cohort studies.

Authors:  P G Toniolo
Journal:  Environ Health Perspect       Date:  1997-04       Impact factor: 9.031

9.  Oestrogen binding and risk factors for breast cancer.

Authors:  D M Ingram; E M Nottage; D L Willcox; A Roberts
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

Review 10.  Estrogen replacement therapy (ERT) in high-risk cancer patients.

Authors:  K A Hutchinson-Williams; J N Gutmann
Journal:  Yale J Biol Med       Date:  1991 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.